An experimental pancreatic cancer drug, daraxonrasib, has demonstrated the ability to double survival rates for patients with advanced pancreatic cancer, according to oncologists. The U.S. Food and Drug Administration has fast-tracked its approval and allowed the drugmaker, Revolution Medicines, to provide the drug to patients outside of clinical trials through an expanded access program. Early results from a Phase 3 clinical trial indicate that patients receiving daraxonrasib alongside chemotherapy experienced significantly longer survival times compared to those receiving chemotherapy alone. In particular, patients treated with the drug had a survival time of approximately 13.2 months, compared to just 6.7 months for those on chemotherapy alone. Daraxonrasib targets the RAS protein, a common mutation in pancreatic cancers that has long been considered “undruggable,” making this development particularly noteworthy in the fight against this aggressive disease.
Why It Matters
Pancreatic cancer has one of the lowest survival rates among all cancers, with only 3% of patients diagnosed with metastatic pancreatic cancer surviving five years post-diagnosis, according to the American Cancer Society. Traditional treatments, including chemotherapy, have proven ineffective for many patients, often leading to a prognosis of less than a year of survival after diagnosis. The advent of daraxonrasib represents a significant breakthrough in treatment options, potentially changing the standard of care for pancreatic cancer, especially as it may benefit a broader range of patients, regardless of specific mutations. The ongoing Phase 3 trial results and the drug’s promising efficacy could redefine treatment strategies in a field where progress has been notoriously slow.
Want More Context? 🔎
